DAX23.409 -0,8%Est505.685 -0,6%MSCI World4.343 -0,1%Top 10 Crypto9,0000 +1,2%Nas22.696 +1,4%Bitcoin60.383 +2,4%Euro1,1663 +0,3%Öl91,13 +1,5%Gold5.179 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Sinkende Ölpreise: DAX mit Gewinnen erwartet -- Erholung an Asiens Börsen -- Trump: Iran-Krieg "so gut wie beendet" -- VW mit Gewinneinbruch 2025 -- HPE, Rheinmetall im Fokus
Top News
Nordex-Aktie: Neue Aufträge über fast 280 MW in Deutschland Nordex-Aktie: Neue Aufträge über fast 280 MW in Deutschland
Dermapharm-Aktie: Dermapharm arbeitet 2025 trotz Umsatzeinbußen profitabler Dermapharm-Aktie: Dermapharm arbeitet 2025 trotz Umsatzeinbußen profitabler
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Transgene Aktie

Kaufen
Verkaufen
Transgene Aktien-Sparplan
0,7700 EUR +0,0120 EUR +1,58 %
STU
0,7960 EUR -0,0240 EUR -2,93 %
PAR
finanzen.net zero
Transgene jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.224,60 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN913048

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0005175080

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTRGNF

Transgene Aktien News

DatumMeistgelesen
GlobeNewswireTransgene to Participate in Upcoming Meetings with Biotech Industry Leaders
GlobeNewswireTransgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
GlobeNewswireTransgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Wer­bungTransgene-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireTransgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
GlobeNewswireTransgene's Combined General Meeting of May 15, 2025
GlobeNewswireTransgene Provides Business and Financial Update for Q1 2025
GlobeNewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2025
GlobeNewswireTransgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
GlobeNewswireAvailability of Transgene’s 2024 Universal Registration Document (URD)
GlobeNewswireTransgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
GlobeNewswireTransgene to Participate in Upcoming Investor Meetings
GlobeNewswireTransgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
GlobeNewswireTransgene to Participate in the Biomed Forum Investor Conference
GlobeNewswireTransgene Announces Financial Calendar for 2025
GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024
GlobeNewswireTransgene Reports Business, Pipeline and Financial Update for Q3 2024
GlobeNewswireTransgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
GlobeNewswireTransgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
GlobeNewswireTransgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
GlobeNewswireTransgene to Present a Poster on Updated Data for TG4050 at SITC 2024
GlobeNewswire2024 Half-Year Financial Report
GlobeNewswireAvailability of Transgene’s Half-Year Financial Report as of June 30, 2024
GlobeNewswireTransgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
GlobeNewswireTransgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
GlobeNewswireTransgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
GlobeNewswireTransgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
GlobeNewswireTransgene to Participate in HTID Conference and Investor Access Forum in Paris
GlobeNewswireTransgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
GlobeNewswireTransgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024
GlobeNewswireTransgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
GlobeNewswireTransgene’s Combined General Meeting of May 15, 2024
GlobeNewswireTransgene provides business and financial update for Q1 2024
GlobeNewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2024
GlobeNewswireAvailability of Transgene's 2023 Universal Registration Document
GlobeNewswireTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
GlobeNewswireTransgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
GlobeNewswireTransgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
GlobeNewswireTransgene Announces Upcoming Investor Meetings
GlobeNewswireTransgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

Transgene News

Transgene News: auf dieser Seite finden Sie alle Transgene News und Nachrichten zur Transgene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Transgene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Transgene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.